Drugs / Avenciguat
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT06272058 | May → Jul 2024 | liver disorder | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT06193811 | Jan → Mar 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05515328 | Sep → Nov 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03842761 | Mar 2019 → Apr 2021 | liver disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03165227 | Oct 2017 → Dec 2019 | diabetic kidney disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03259464 | Sep 2017 → May 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03116906 | Apr 2017 → Jun 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03116893 | Apr → May 2017 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02694354 | Mar → Apr 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT06082843 | Jan → May 2024 | cirrhosis of liver, portal hypertension | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 2 | NCT05559580 | Dec 2022 → Oct 2025 | systemic sclerosis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT05282121 | Jun 2022 → Apr 2024 | portal hypertension | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 2 | NCT05161481 | Apr 2022 → May 2024 | portal hypertension | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 2 | NCT04750577 | Apr 2021 → Nov 2022 | diabetic kidney disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT04736628 | Apr 2021 → Aug 2023 | chronic kidney disease | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Avenciguat | “Mass balance and absolute bioavailability of avenciguat ((14)C) after intravenous or oral administration in healthy male participants.” PMID 41489441 ↗ Jan 2026 |
| Known as | BI 685509 | “Avenciguat (BI 685509) is a medicine that is being developed to treat high blood pressure in the portal vein (main vessel going to the liver).” NCT06272058 ↗10“Avenciguat (BI 685509) TF2 (Reference, R) vs. Avenciguat (BI 685509) iCF (Test 1, T1) tablets under fasted conditions” NCT06193811 ↗ “Avenciguat (BI 685509)” NCT05161481 ↗ “Avenciguat (BI 685509)” NCT05559580 ↗ |
| Action | Activate | “BI 685509, a soluble guanylyl cyclase activator” PMID 38789635 ↗ May 2024 |
| Modality | Small molecule | — CHEMBL5314503 ↗ |
| Route | Oral | “BI 685509 was rapidly absorbed after oral administration” PMID 38789635 ↗ May 2024 |